Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 2
2006 1
2007 3
2008 3
2009 2
2010 7
2011 6
2012 4
2013 11
2014 11
2015 13
2016 7
2017 7
2018 8
2019 4
2020 1
2021 6
2022 8
2023 11
2024 7
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Cipriani A, et al. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477251 Free PMC article. Review.
In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2.13 (95% credible interval [CrI] 1.89-2.41) for amitriptyline and 1.37 (1.16-1.63) for reboxetine. For acceptability, only agomelatine (OR 0.84, 95% CrI 0.72-0.97) and flu …
In terms of efficacy, all antidepressants were more effective than placebo, with ORs ranging between 2.13 (95% credible interval [CrI] 1.89- …
Antidepressant efficacy of Agomelatine: Meta-analysis of placebo controlled and active comparator studies.
Maddukuri RK, Hema C, Sri Tejaswi K, Venkata Mounika M, Vegesana BP. Maddukuri RK, et al. Asian J Psychiatr. 2021 Nov;65:102866. doi: 10.1016/j.ajp.2021.102866. Epub 2021 Sep 20. Asian J Psychiatr. 2021. PMID: 34592623 Review.
Agomelatine is a novel antidepressant that was developed to counter the adverse effects associated with the standard SSRIs and SNRIs that limited their usage. ...In comparison (RR 0.99, 0.92-1.07) Agomelatine is an effective antidepressant having similar efficacy wi …
Agomelatine is a novel antidepressant that was developed to counter the adverse effects associated with the standard SSRIs and SNRIs …
Agomelatine versus other antidepressive agents for major depression.
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Guaiana G, et al. Cochrane Database Syst Rev. 2013 Dec 17;2013(12):CD008851. doi: 10.1002/14651858.CD008851.pub2. Cochrane Database Syst Rev. 2013. PMID: 24343836 Free PMC article. Review.
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depressive disorder in comparison with other antidepressants, 2) to review the acceptability of agomelatine in comparison with other antid …
OBJECTIVES: The objective of this review was 1) to determine the efficacy of agomelatine in alleviating acute symptoms of major depre …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirta …
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, …
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Koesters M, et al. Br J Psychiatry. 2013 Sep;203(3):179-87. doi: 10.1192/bjp.bp.112.120196. Br J Psychiatry. 2013. PMID: 23999482 Review.
BACKGROUND: Agomelatine is a novel antidepressant drug with narrative, non-systematic reviews making claims of efficacy. ...Data extracted from three relapse prevention studies failed to show significant effects of agomelatine over placebo (relative risk 0.78, 99% C …
BACKGROUND: Agomelatine is a novel antidepressant drug with narrative, non-systematic reviews making claims of efficacy. ...Data extr …
Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials.
Chen Y, Li J, Liao M, He Y, Dang C, Yu J, Xing S, Zeng J. Chen Y, et al. Int Clin Psychopharmacol. 2024 May 1;39(3):163-173. doi: 10.1097/YIC.0000000000000509. Epub 2024 Mar 25. Int Clin Psychopharmacol. 2024. PMID: 37781768
Agomelatine is effective in the treatment of depression, but its effect for post-stroke depression (PSD) remains unclear. ...After 6-12 weeks of treatment, the HAMD score ( P = 0.16) and the overall response rates ( P = 0.20) in the agomelatine group were comparable …
Agomelatine is effective in the treatment of depression, but its effect for post-stroke depression (PSD) remains unclear. ...After 6- …
Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Slee A, et al. Lancet. 2019 Feb 23;393(10173):768-777. doi: 10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31. Lancet. 2019. PMID: 30712879
Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes. ...
Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findin …
Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients.
Hood SD, Odufowora-Sita O, Briere JB, Lucchino M, Khrouf F, Olewinska E, Pierzchala P, Mezghani M, Nikodem M, Lévy P. Hood SD, et al. Int Clin Psychopharmacol. 2025 Mar 1;40(2):62-74. doi: 10.1097/YIC.0000000000000551. Epub 2024 May 20. Int Clin Psychopharmacol. 2025. PMID: 38804215 Free PMC article.
For the other comparators, the results were nonsignificant; however, all the point estimates were in favor of agomelatine. Similarly, for discontinuation because of AEs, the point estimates leaned consistently toward agomelatine suggesting its higher tolerability. . …
For the other comparators, the results were nonsignificant; however, all the point estimates were in favor of agomelatine. Similarly, …
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
Singh SP, Singh V, Kar N. Singh SP, et al. Int J Neuropsychopharmacol. 2012 Apr;15(3):417-28. doi: 10.1017/S1461145711001301. Epub 2011 Aug 23. Int J Neuropsychopharmacol. 2012. PMID: 21859514 Free article. Review.
Summary effect sizes of various groups and subgroups were computed from SMDs between agomelatine and control (placebo or antidepressants) arms. There were nine trials involving 3943 severe cases of depression on agomelatine (n=2390) and either placebo (n=689) or ant …
Summary effect sizes of various groups and subgroups were computed from SMDs between agomelatine and control (placebo or antidepressa …
Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.
Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Oliva V, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33549697
Eligible studies had to focus on the use of at least one of 15 antidepressants commonly used in MDD (i.e., agomelatine, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, mirtazapine, paroxetine, reboxetine, sertralin …
Eligible studies had to focus on the use of at least one of 15 antidepressants commonly used in MDD (i.e., agomelatine, bupropion, ci …
110 results

Searches related to "agomelatine"